Get the Stockscreener App
8.97
1.43%
-0.13
After Hours:
8.90
-0.07
-0.78%
Prothena Corporation Plc stock is traded at $8.97, with a volume of 636.41K.
It is down -1.43% in the last 24 hours and down -18.97% over the past month.
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
See More
Previous Close:
$9.10
Open:
$9.01
24h Volume:
636.41K
Relative Volume:
0.99
Market Cap:
$482.85M
Revenue:
$217.25M
Net Income/Loss:
$-50.92M
P/E Ratio:
-8.97
EPS:
-1
Net Cash Flow:
$-100.85M
1W Performance:
-3.65%
1M Performance:
-18.97%
6M Performance:
+39.39%
1Y Performance:
-31.79%
1-Day Range:
$8.885
$9.14
1-Week Range:
$8.885
$9.69
52-Week Range:
$4.32
$16.66
Prothena Corporation Plc Stock (PRTA) Company Profile
Name
Prothena Corporation Plc
Sector
Industry
Phone
011-353-1-236-2500
Address
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
Compare PRTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRTA
Prothena Corporation Plc
|
8.97 | 489.85M | 217.25M | -50.92M | -100.85M | -1.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Prothena Corporation Plc Stock (PRTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Downgrade | BofA Securities | Neutral → Underperform |
| May-27-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-27-25 | Downgrade | Jefferies | Buy → Hold |
| May-27-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Apr-24-23 | Initiated | SVB Securities | Outperform |
| Jan-27-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-28-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Jun-18-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-08-21 | Reiterated | Oppenheimer | Outperform |
| May-26-21 | Initiated | Citigroup | Buy |
| Feb-26-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-12-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-02-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-07-20 | Initiated | H.C. Wainwright | Buy |
| Jul-09-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-19-19 | Upgrade | Evercore ISI | In-line → Outperform |
| May-21-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-23-18 | Downgrade | Jefferies | Buy → Hold |
| Apr-05-18 | Reiterated | Barclays | Overweight |
| Nov-20-17 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-29-17 | Reiterated | BTIG Research | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Jefferies | Buy |
| Apr-12-17 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-17 | Initiated | Piper Jaffray | Overweight |
| Mar-02-17 | Initiated | Instinet | Buy |
| Dec-21-16 | Initiated | SunTrust | Buy |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Aug-04-16 | Reiterated | Barclays | Overweight |
| May-13-16 | Initiated | Barclays | Overweight |
| Feb-19-16 | Reiterated | Wedbush | Outperform |
| Jan-21-16 | Initiated | Credit Suisse | Outperform |
View All
Prothena Corporation Plc Stock (PRTA) Latest News
How Are Partnered Pipelines Rewriting The Prothena (PRTA) Narrative And Price Target Outlook - Yahoo Finance UK
Macro Review: What valuation multiples suggest for Prothena Corporation plc stockWeekly Profit Summary & Long Hold Capital Preservation Plans - moha.gov.vn
We Think Prothena (NASDAQ:PRTA) Can Afford To Drive Business Growth - Yahoo Finance
(PRTA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Prothena announces board of directors update - MSN
89,704 Shares in Prothena Corporation plc $PRTA Acquired by Assenagon Asset Management S.A. - Defense World
(PRTA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Prothena Corporation plc(NasdaqGS:PRTA) added to S&P Biotechnology Select Industry Index - marketscreener.com
Squarepoint Ops LLC Takes $1.27 Million Position in Prothena Corporation plc $PRTA - Defense World
Earnings Miss: Why Prothena Corporation plc stock remains undervaluedStock Surge & Fast Entry Momentum Trade Alerts - Улправда
Why Prothena Corporation plc stock remains undervaluedDip Buying & Free High Return Stock Watch Alerts - Улправда
What catalysts could drive Prothena Corporation plc stock higherDip Buying & AI Based Trade Execution Alerts - DonanımHaber
Prothena Corporation plc (NASDAQ:PRTA) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Birchview Capital LP Has $2.74 Million Stock Holdings in Prothena Corporation plc $PRTA - MarketBeat
Prothena Board Member Paula Cobb Resigns - The Globe and Mail
Paula Cobb steps down from Prothena’s board to join Manifold Bio - Investing.com Nigeria
Paula Cobb steps down from Prothena’s board to join Manifold Bio By Investing.com - Investing.com South Africa
[8-K] PROTHENA CORP PUBLIC LTD CO Reports Material Event | PRTA SEC FilingForm 8-K - Stock Titan
Prothena Announces Board of Directors Update - Yahoo Finance
What analysts say about Prothena Corporation plc stockMean Reversion Trades & Free Harness Proven Investment Plans - earlytimes.in
Prothena Corporation plc $PRTA Shares Bought by Federated Hermes Inc. - MarketBeat
Liquidity Mapping Around (PRTA) Price Events - Stock Traders Daily
Prothena (PRTA) price target increased by 10.91% to 20.74 - MSN
Ready to Jump After Recent Trade: Prothena Corporation plc (PRTA) - setenews.com
How the Narrative Surrounding Prothena Is Changing After New Pipeline and Valuation Updates - Yahoo Finance
Prothena (PRTA) Price Target Increased by 10.91% to 20.74 - Nasdaq
Will Prothena Corporation plc stock outperform international peersTrade Entry Summary & Breakout Confirmation Trade Signals - Newser
Prothena (NASDAQ:PRTA) Stock Price Up 7.4%Here's Why - MarketBeat
Are Smart Investors Making the Right Decision? Prothena Corporation plc (PRTA) - setenews.com
Prothena Corp (PRTA) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Citizens Jmp Forecasts Strong Price Appreciation for Prothena (NASDAQ:PRTA) Stock - MarketBeat
Prothena (NASDAQ:PRTA) Price Target Raised to $19.00 at Citizens Jmp - Defense World
Prothena stock price target raised to $19 from $11 at Citizens - Investing.com Nigeria
Prothena stock price target raised to $19 from $11 at Citizens By Investing.com - Investing.com South Africa
Citizens Raises Price Target for Prothena Corp (PRTA) to $19.00 - GuruFocus
Prothena Corporation plc Stock Analysis and ForecastFundamental Stock Analysis & Double Digit Portfolio Growth - earlytimes.in
Why (PRTA) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Aug PreEarnings: Why Prothena Corporation plc stock remains undervaluedRecession Risk & Target Return Focused Stock Picks - BỘ NỘI VỤ
DCF Advisers LLC Lowers Stock Position in Prothena Corporation plc $PRTA - MarketBeat
Prothena Corporation plc (NASDAQ:PRTA) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Prothena Corporation plc $PRTA Position Lessened by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
Prothena (NASDAQ:PRTA) Upgraded at Chardan Capital - Defense World
How Prothena Corporation plc stock performs during Fed tightening cyclesJuly 2025 Reactions & Low Risk Entry Point Guides - newser.com
Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025 - BioSpace
Will Prothena Corporation plc stock see PE expansionQuarterly Growth Report & Free Reliable Trade Execution Plans - newser.com
Prothena Shareholders Approve Capital Reduction Proposal - TipRanks
Prothena presents TDP-43 CYTOPE data showing promise for ALS treatment - Investing.com Australia
Prothena (PRTA) Highlights Breakthrough in Drug Delivery at Neur - GuruFocus
Prothena announces poster presentation on its TDP-43 Cytope® program at neuroscience 2025 - MarketScreener
Prothena Announces Poster Presentation On Its TDP-43 Cytope® Program At Neuroscience 2025 - TradingView
Prothena Corporation Plc Stock (PRTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):